BioCentury
ARTICLE | Finance

Funding antifungals

Why F2G is sticking with private markets to fund its novel antifungal

June 27, 2016 7:00 AM UTC

On the back of encouraging clinical data for a novel antifungal, a syndicate supplied F2G Ltd. with one of the largest U.K. venture rounds this year.

New investor Sectoral Asset Management led the $60 million tranched series E round. Other new investors Novo A/S, Aisling Capital and Brace Pharma Capital joined existing investors Advent Life Sciences, Novartis Venture Fund, Sunstone Capital and Merifin Capital...